Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating expenses:
Research and development	$ 60,874	$ 73,044	$ 117,322	$ 140,210
Research and development related success payments and contingent consideration	(27,944)	26,679	10,063	26,799
General and administrative	16,442	16,566	32,711	33,332
Total operating expenses	49,372	116,289	160,096	200,341
Loss from operations	(49,372)	(116,289)	(160,096)	(200,341)
Interest income, net	3,202	2,374	6,236	4,350
Other expense, net	(4,121)	(84)	(3,906)	(131)
Net loss	$ (50,291)	$ (113,999)	$ (157,766)	$ (196,122)
Net loss per common share - basic	$ (0.21)	$ (0.59)	$ (0.7)	$ (1.02)
Net loss per common share - diluted	$ (0.21)	$ (0.59)	$ (0.7)	$ (1.02)
Weighted-average number of common shares - basic	234,440	192,540	225,872	191,888
Weighted-average number of common shares - diluted	234,440	192,540	225,872	191,888